Publications

• 04.30.2020  |  A One Health framework to estimate costs of antimicrobial resistance Download
• 04.20.2020  |  Lancet Infectious Diseases – The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later Download
• 01.30.2020  |  Clinical Infectious Diseases – Antibiotic development incentives that reflect societal value of antibiotics Download
• 11.19.2019  |  Nature Microbiology – The global preclinical antibacterial pipeline Download
• 11.19.2019  |  Nature Microbiology – Antibiotic development – economic, regulatory and societal challenges Download
• 10.30.2019  |  Lancet – A roadmap for sustainably governing the global antimicrobial commons Download
• 10.02.2019  |  Nature Biotechnology – A shot in the arm for new antibiotics Download
• 07.31.2019  |  Nature Communications – Designing development programs for non-traditional antibacterial agents Download
• 10.16.2018  |  PLOS ONE – Introduction and geographic availability of new antibiotics approved between 1999 and 2014 Download
• 10.01.2018  |  US National Action Plan for Combating Antibiotic-Resistant Bacteria: Progress Report: Year 3 – US Government CARB Task Force | Task Force provides an update on progress it is making on its 2015 commitment to slow the emergence of resistant bacteria and prevent the spread of resistant infections, strengthen national one-health surveillance, advance development and use of rapid diagnostic tests and characterization of resistant bacteria, accelerate basic and applied R&D for new antibiotics and other therapeutics, and improve international collaboration for prevention, surveillance, control and R&D. Download
• 07.17.2018  |  Journal of Law, Medicine, & Ethics – A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All Download
• 06.22.2018  |  World Economic Forum report in collaboration with Wellcome Trust: Not enough new antibiotics are in development to guarantee that we can continue to treat infections. This briefing outlines why pull incentives are necessary in addition to push funding, some of the key challenges they need to address and next steps towards implementing or piloting a pull incentive. Download
• 04.05.2018  |  J Pharm Policy Pract – Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations Download
• 01.15.2018  |  Drive-AB Report: Revitalizing the antibiotic pipeline Download
• 01.10.2018  |  Qualified Infectious Disease Product Designation Questions and Answers Guidance for Industry Download